These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9698685)

  • 21. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
    Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
    J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
    Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
    Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 24. Pergolide mesylate in Parkinson's disease treatment.
    Pezzoli G; Canesi M; Pesenti A; Mariani CB
    J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pergolide-induced ergotism.
    Morgan JC; Sethi KD
    Neurology; 2006 Jul; 67(1):104. PubMed ID: 16832086
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.
    Crevits L; Versijpt J; Hanse M; De Ridder K
    Neuropsychobiology; 2000; 42(4):202-6. PubMed ID: 11096336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valvular health disease with pergolide.
    Prescrire Int; 2003 Dec; 12(68):225. PubMed ID: 14986695
    [No Abstract]   [Full Text] [Related]  

  • 34. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ
    Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
    [No Abstract]   [Full Text] [Related]  

  • 36. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sleep attacks and pergolide mesylate].
    García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
    Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
    [No Abstract]   [Full Text] [Related]  

  • 38. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
    Schwarz J; Scheidtmann K; Trenkwalder C
    Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide.
    Balachandran KP; Stewart D; Berg GA; Oldroyd KG
    Postgrad Med J; 2002 Jan; 78(915):49-50. PubMed ID: 11796875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
    Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
    Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.